指南与共识乳腺癌

晚期乳腺癌二代测序临床应用专家共识(2024版)

[Expert consensus on clinical application of next-generation sequencing in advanced breast cancer (2024 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2024-01-01

乳腺癌是全球女性最常见的恶性肿瘤,2020年全球新发约226万例,占所有恶性肿瘤新发病例的11.7%。中国抗癌协会国际医疗与交流分会和中国医师协会肿瘤医师分会组织专家制定本共识,采用新的循证医学证据,旨在为晚期乳腺癌患者提供更全面的基因检测信息以制定更精准的治疗策略。

要点

  • 2020年全球新发乳腺癌约226万例,占所有恶性肿瘤新发病例的11.7%。
  • 基因靶向治疗显著延长晚期乳腺癌患者生存时间,对分子病理诊断、靶向药物选择及治疗模式优化有重要意义。
  • 2024版共识采用新的循证医学证据,较2021版旨在提供更全面的基因检测信息。

核心结论

  • 2024版共识采用新的循证医学证据,旨在为晚期乳腺癌患者提供更全面的基因检测信息,从而制定更精准的治疗策略。

研究设计与样本

  • 中国抗癌协会国际医疗与交流分会和中国医师协会肿瘤医师分会组织专家制定《晚期乳腺癌二代测序临床应用专家共识(2024版)》。

主要发现

  • 根据世界卫生组织数据,2020年全球新发乳腺癌病例约226万,占所有恶性肿瘤新发病例的11.7%。
  • 基因靶向治疗显著延长了晚期乳腺癌患者的生存时间,在分子病理诊断、靶向药物选择以及治疗模式优化方面具有重要意义。
  • 2024版共识相较于《晚期乳腺癌基因检测热点问题中国专家共识(2021版)》采用了新的循证医学证据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignant tumor among women in the world. According to data from the World Health Organization, in 2020, there were approximately 2.26 million new breast cancer cases worldwide, accounting for 11.7% of all new cancer cases. In recent years, with the rapid development of molecular biology and gene detection technology, the research on advanced breast cancer continues to deepen, and the treatment methods are constantly enriched. Gene targeted therapy significantly prolongs the survival period of patients with advanced breast cancer, which is of great significance for molecular pathological diagnosis, targeted drug selection and treatment mode optimization of patients with advanced breast cancer. Based on the development of literature and clinical research, the consensus expert committee formulated the "Expert consensus on clinical application of next-generation sequencing in advanced breast cancer (2024 edition)". Compared with the "Chinese Expert Consensus on Hot Issues of Gene Testing for Advanced breast cancer (2021)", the 2024 consensus adopts new evidence-based medical evidence, aiming to provide more comprehensive gene testing information for patients with advanced breast cancer, so as to develop more accurate treatment strategies. 乳腺癌是全球女性最常见的恶性肿瘤,根据世界卫生组织的数据,2020年,全球新发乳腺癌病例约226万,占所有恶性肿瘤新发病例的11.7%。近年来,随着分子生物学和基因检测技术的飞速发展,晚期乳腺癌相关研究不断深入,治疗手段也不断丰富。基因靶向治疗显著延长了晚期乳腺癌患者的生存时间,在晚期乳腺癌患者的分子病理诊断、靶向药物选择以及治疗模式优化方面具有重要意义。基于文献及临床研究的发展,中国抗癌协会国际医疗与交流分会和中国医师协会肿瘤医师分会组织专家制定了《晚期乳腺癌二代测序临床应用专家共识(2024版)》,相较于《晚期乳腺癌基因检测热点问题中国专家共识(2021版)》,2024版共识采用了新的循证医学证据,旨在为晚期乳腺癌患者提供更全面的基因检测信息,从而制定更精准的治疗策略。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Expert consensus on clinical application of next-generation sequencing in advanced breast cancer (2024 edition)]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 39690541. doi:10.3760/cma.j.cn112152-20240104-00006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。